Transcription factors may inadvertently lock in DNA mistakes

October 21, 2020

DURHAM, N.C. -- Transcription factor proteins are the light switches of the human genome. By binding to DNA, they help turn genes "on" or "off" and start the important process of copying DNA into an RNA template that acts as a blueprint for a new protein.

By being choosy about which genes they turn on, transcription factors determine which rooms in the house are lighted and which aren't, or rather, which components of a person's genome are activated.

A team of Duke researchers has found that transcription factors have a tendency to bind strongly to "mismatched" sections of DNA, sections of the code that were not copied correctly. The strong binding of transcription factors to mismatched sections of regulatory DNA might be a way in which random mutations become a problem that leads to disease, including cancer.

The findings appear Oct. 21 in the journal Nature.

Most of the time, DNA replication in the body goes smoothly, with nucleotides locking arms with their complementary base pair and marching through the cycle together in intended A-T and C-G fashion. However, as Gordan describes it, "no polymerase is perfect" and every now and then, a nucleotide will be paired with the wrong partner, resulting in a mismatch.

Pipetting transcription factor proteins on slides pre-blotted with thousands of DNA molecule samples, a research team led by Duke computational biologist Raluca Gordan Ph.D., showed that the proteins had a stronger bond with the sections of DNA with the mismatched base pairs than with those with perfectly matched base pairs, or "normal" DNA structure.

But what makes these 'mistakes' an attractive binding site for transcription factor proteins? For insight, Gordan, an associate professor in the Department of Biostatistics and Bioinformatics and the Department of Computer Science, reached out to Hashim Al-Hashimi, Ph.D., a James B. Duke Professor of Biochemistry, and expert in DNA structure and dynamics who works just across the street.

Al-Hashimi studies nucleic acids (DNA and RNA) and their interactions with proteins and small molecules, with the idea that how these biomolecules look and move is as important for their function as their chemical properties.

Looking at the experimental results, Gordan and Al-Hashimi came to the conclusion that the strong interaction between transcription factor proteins and mismatched DNA has a lot to do with laziness. When a transcription factor protein binds to DNA, it must spend energy distorting the site, for example by bending the DNA to its will. However, mismatched sections of DNA are already distorted, so the transcription factor protein has to do less work.

"That's when the transcription factor doesn't need to pay that energetic penalty" to get the job done, Gordan said.

"If we are ever to attain a deep and predictive understanding of how DNA is recognized by proteins in cells, we need to go beyond the conventional description in terms of static structures and move towards describing both DNA and the protein molecules that bind to them in terms of dynamic structures that have different preferences to adopt a wide range of shapes," Al-Hashimi said.

Gordan said that going forward, the team hopes to understand how this interaction relates to disease development. If a mismatched base pair, bound strongly by a transcription factor, makes it through the DNA replication cycle without being repaired by another type of protein--known as a repair enzyme--it can become a mutation, and mutations can lead to genetic diseases like cancer and neurodegeneration.

"We are now convinced that the interactions between transcription factors and mismatches are really strong," she said. "So the next step is to understand what this means for the cell."

"We already know that regulatory regions of the genome harbor more cancer mutations than expected by chance. We just do not know why. The strong interactions between transcription factors and DNA mismatches, which could interfere with repair of the mismatches, provide a novel mechanism for the accumulation of mutations in regulatory DNA."
Six research groups from the United States and Israel contributed to the project, including the Duke research team of Maria Schumacher, Ph.D., Nanaline H. Duke Distinguished Professor of Biochemistry. The authors dedicated the paper to the memory of Rosalind E. Franklin, on the occasion of her 100th birthday anniversary.

Pilot funding was provided by the Duke Center for Genomic and Computational Biology, and the project is now funded through a recently awarded NIH R01 grant, "The role of transcription factor proteins in mutagenesis at regulatory sites."

CITATION: "DNA Mismatches Reveal Conformational Penalties in Protein-DNA Recognition," Ariel Afek, Honglue Shi, Atul Rangadurai, Harshit Sahay, Alon Senitzki, Suela Xhani, Mimi Fang, Raul Salinas, Zachery Mielko, Miles A. Pufall, Gregory M.K. Poon, Tali E. Haran, Maria A. Schumacher, Hashim M. Al-Hashimi, Raluca Gordan. Nature, Oct. 21, 2020. DOI: 10.1038/s41586-020-2843-2

Duke University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to